search
Back to results

Sentinel NOSE Study: Prospective Registration Study on the Sentinel Node Procedure for Bulky Squamous Cell Carcinoma of the Nasal Vestibule.

Primary Purpose

Squamous Cell Carcinoma of the Nasal Vestibule

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Sentinel node procedure
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Squamous Cell Carcinoma of the Nasal Vestibule focused on measuring nasal vestibule, sentinel node, nodal metastases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Aged 18 years or older. WHO performance score of 0, 1 or 2. Newly diagnosed T1 or T2 squamous cell carcinoma of the nasal vestibule. Tumor diameter ≥1.5 cm and/or tumor volume ≥1.5cm3 Clinically negative neck (N0). Patients planned to undergo curative treatment. Patient provided written informed consent Exclusion Criteria: Prior allergic reaction to either indocyanide green, 99m-Technetium nanocolloid or human colloidal albumin. Pregnancy. Previous surgery or radiotherapy of the neck. Concurrent secondary head-and-neck tumor. Unable to provide informed consent

Sites / Locations

  • Anthoni van Leeuwenhoekhuis
  • Radboud UMCRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

sentinel node procedure

Arm Description

Participants will indergo the standard treatment for their disease ( i.e. brachytherapy) but a sentinel node procedure will be added to their treatment

Outcomes

Primary Outcome Measures

Feasibility of identification of sentinel nodes
the number of identified nodes on SPECT that can actually be retrieved at subsequent surgery

Secondary Outcome Measures

pain scores
Pain scores during and immediately after the injection of nanocolloid on a visual anlog scale ranging from 0-10
analgetics
use of analgetics ( both orally and locally administered)
surgical complications
complications after surgery as registered in our hospital record database

Full Information

First Posted
November 19, 2020
Last Updated
March 29, 2023
Sponsor
Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05637307
Brief Title
Sentinel NOSE Study: Prospective Registration Study on the Sentinel Node Procedure for Bulky Squamous Cell Carcinoma of the Nasal Vestibule.
Official Title
Sentinel NOSE Study: Prospective Registration Study on the Sentinel Node Procedure for Bulky Squamous Cell Carcinoma of the Nasal Vestibule
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 15, 2020 (Actual)
Primary Completion Date
June 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Management of the neck in Wang cT1-T2N0 nasal vestibule carcinoma (NVC) has been an ongoing point of discussion. As the disease is rare publications are scarce and published regional recurrence rates vary widely between 0% up to 23%. In general, literature recommends adequate radiological neck staging followed by a watchful waiting policy, as overall regional recurrence rates are low (5-10%). However, according to recent findings, a subset of patients with large or voluminous cT1-T2N0 NVC is deemed at high risk of nodal involvement (20-40% regional recurrence) but receive no elective treatment, although it is well known that presence of nodal metastases impacts the prognosis of head and neck cancer (HNC) dramatically. Whereas elective neck dissection may be too aggressive, sentinel node biopsy (SNB) has been proven a reliable and safe alternative to bridge the gap between imaging and neck dissection. SNB is currently routinely employed in most HNC centres in the Netherlands and is considered state of the art care, but its application in HNC is limited to oral cavity carcinoma and squamous cell carcinoma of the skin. Following the observation of increased risk of (occult) nodal metastases and regional recurrence in bulky tumors, the sentinel node procedure seems ideally suited for cT1-T2N0 NVC patients. Its superficial tumor localization is easily accessible for peritumoral Tc-99m-nanocolloid-ICG tracer injection. The purpose of this prospective registration study is to document the clinical introduction of the sentinel node procedure for bulky nasal vestibule carcinoma in our centre by protocol, and to identify and address possible unexpected difficulties specific for this tumor site. Ultimately, the goal will be routine and wide implementation of SNB in the NVC subgroup known to be at risk of nodal involvement, as a means to improve regional disease staging and control. Objective: To prospectively document the introduction of the sentinel node procedure for bulky cT1-T2N0 nasal vestibule carcinoma in patients at risk of nodal involvement. Study design: Single centre prospective registration study. To be extended with a second centre. Study population: Patients with Wang cT1-T2N0 squamous cell carcinoma of the nasal vestibule, with tumor diameter ≥1.5 cm and/or tumor volume ≥1.5 cm3, with a WHO performance score of 2 or lower and no history of previous surgery or radiotherapy of the neck. Interventions: 1. Subcutaneous peritumoral radioactive tracer injection followed by lymphoscintigraphy and Single Photon Emission Computed Tomography (SPECT) imaging for sentinel lymph node visualization. 2. Surgical sentinel node biopsy and histopathological examination of harvested nodes following the abovementioned imaging. Main study parameters/endpoints: The primary endpoint of this study will be successful identification of sentinel nodes on lymphoscintigraphy and SPECT imaging. The procedure will be considered feasible when one or more sentinel nodes can be identified and localized in at least 7 out of the 10 patients..
Detailed Description
Management of the neck in Wang cT1-T2N0 nasal vestibule carcinoma (NVC) has been an ongoing point of discussion. As the disease is rare publications are scarce and published regional recurrence rates vary widely between 0% up to 23%. In general, literature recommends adequate radiological neck staging followed by a watchful waiting policy, as overall regional recurrence rates are low (5-10%). However, according to recent findings, a subset of patients with large or voluminous cT1-T2N0 NVC is deemed at high risk of nodal involvement (20-40% regional recurrence) but receive no elective treatment, although it is well known that presence of nodal metastases impacts the prognosis of head and neck cancer (HNC) dramatically. Whereas elective neck dissection may be too aggressive, sentinel node biopsy (SNB) has been proven a reliable and safe alternative to bridge the gap between imaging and neck dissection. SNB is currently routinely employed in most HNC centres in the Netherlands and is considered state of the art care, but its application in HNC is limited to oral cavity carcinoma and squamous cell carcinoma of the skin. Following the observation of increased risk of (occult) nodal metastases and regional recurrence in bulky tumors, the sentinel node procedure seems ideally suited for cT1-T2N0 NVC patients. Its superficial tumor localization is easily accessible for peritumoral Tc-99m-nanocolloid-ICG tracer injection. The purpose of this prospective registration study is to document the clinical introduction of the sentinel node procedure for bulky nasal vestibule carcinoma in our centre by protocol, and to identify and address possible unexpected difficulties specific for this tumor site. Ultimately, the goal will be routine and wide implementation of SNB in the NVC subgroup known to be at risk of nodal involvement, as a means to improve regional disease staging and control. Objective: To prospectively document the introduction of the sentinel node procedure for bulky cT1-T2N0 nasal vestibule carcinoma in patients at risk of nodal involvement. Study design: Single centre prospective registration study. To be extended with a second centre. Study population: Patients with Wang cT1-T2N0 squamous cell carcinoma of the nasal vestibule, with tumor diameter ≥1.5 cm and/or tumor volume ≥1.5 cm3, with a WHO performance score of 2 or lower and no history of previous surgery or radiotherapy of the neck. Interventions: 1. Subcutaneous peritumoral radioactive tracer injection followed by lymphoscintigraphy and Single Photon Emission Computed Tomography (SPECT) imaging for sentinel lymph node visualization. 2. Surgical sentinel node biopsy and histopathological examination of harvested nodes following the abovementioned imaging. Main study parameters/endpoints: The primary endpoint of this study will be successful identification of sentinel nodes on lymphoscintigraphy and SPECT imaging. The procedure will be considered feasible when one or more sentinel nodes can be identified and localized in at least 7 out of the 10 patients.. The secondary outcomes will be: yield of at least one lymph node after biopsy, incidence of surgical complications and pain score during and after peritumoral tracer injection and tracer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Squamous Cell Carcinoma of the Nasal Vestibule
Keywords
nasal vestibule, sentinel node, nodal metastases

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
sentinel node procedure
Arm Type
Experimental
Arm Description
Participants will indergo the standard treatment for their disease ( i.e. brachytherapy) but a sentinel node procedure will be added to their treatment
Intervention Type
Procedure
Intervention Name(s)
Sentinel node procedure
Intervention Description
Injection of radio-active tracer in the tumor before brachytherapy treatment, visualization of sentinel nodes by SPECT, and extirpation of sentinel nodes by surgery
Primary Outcome Measure Information:
Title
Feasibility of identification of sentinel nodes
Description
the number of identified nodes on SPECT that can actually be retrieved at subsequent surgery
Time Frame
1 week
Secondary Outcome Measure Information:
Title
pain scores
Description
Pain scores during and immediately after the injection of nanocolloid on a visual anlog scale ranging from 0-10
Time Frame
2 hours after injection
Title
analgetics
Description
use of analgetics ( both orally and locally administered)
Time Frame
2 hours after injection
Title
surgical complications
Description
complications after surgery as registered in our hospital record database
Time Frame
30 days after the procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18 years or older. WHO performance score of 0, 1 or 2. Newly diagnosed T1 or T2 squamous cell carcinoma of the nasal vestibule. Tumor diameter ≥1.5 cm and/or tumor volume ≥1.5cm3 Clinically negative neck (N0). Patients planned to undergo curative treatment. Patient provided written informed consent Exclusion Criteria: Prior allergic reaction to either indocyanide green, 99m-Technetium nanocolloid or human colloidal albumin. Pregnancy. Previous surgery or radiotherapy of the neck. Concurrent secondary head-and-neck tumor. Unable to provide informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michal Czwerwinski, MD
Phone
00623172667
Email
michal.czerwinski@radboudumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Lia Verhoef, MD, PhD
Phone
00611079633
Email
lia.verhoef@radboudumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hans Kaanders, Prof., PhD, MD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Anthoni van Leeuwenhoekhuis
City
Amsterdam
ZIP/Postal Code
1086 CX
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abrahim Al-Mamgami, MD, PHD
Facility Name
Radboud UMC
City
Nijmegen
ZIP/Postal Code
6500 HB
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michal Czerwinski, MD
Phone
00623172667
Email
michal.czerwinski@radboudumc.nl
First Name & Middle Initial & Last Name & Degree
Lia Verhoef, MD, PhD
Phone
00611079633
Email
lia.verhoef@radboudumc.nl

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data wil be available upon request
IPD Sharing Time Frame
after closure of the study ( i.e.in 2 years time) for a time period of 5 years
IPD Sharing Access Criteria
upon request

Learn more about this trial

Sentinel NOSE Study: Prospective Registration Study on the Sentinel Node Procedure for Bulky Squamous Cell Carcinoma of the Nasal Vestibule.

We'll reach out to this number within 24 hrs